• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Res . Persistence of dysfunctional immune response 12 months after SARS-CoV-2 infection and their relationship with pulmonary sequelae and l

tetano

Editor, Senior Moderator
Respir Res


. 2025 Apr 17;26(1):152.
doi: 10.1186/s12931-025-03200-1. Persistence of dysfunctional immune response 12 months after SARS-CoV-2 infection and their relationship with pulmonary sequelae and long COVID

Tamara Cruz[SUP] 1 2 [/SUP], Núria Albacar[SUP] 1 2 3 [/SUP], Estibaliz Ruiz[SUP] 1 4 [/SUP], Gema M Lledo[SUP] 5 [/SUP], Lídia Perea[SUP] 1 2 [/SUP], Alba Puebla[SUP] 1 [/SUP], Alejandro Torvisco[SUP] 1 6 [/SUP], Núria Mendoza[SUP] 1 [/SUP], Pau Marrades[SUP] 3 [/SUP], Jacobo Sellares[SUP] 1 2 3 [/SUP], Alvar Agustí[SUP] 1 2 3 [/SUP], Odette Viñas[SUP] 1 4 [/SUP], Oriol Sibila[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Rosa Faner[SUP] #[/SUP][SUP] 7 8 9 [/SUP]



Affiliations
Abstract

Introduction: Most patients recover fully after an acute infection by SARS-CoV-2. Some, however, may develop pulmonary sequelae (PS) and/or long COVID (LC). However, whether these two clinical conditions have similar or different pathogenic mechanisms is unknown.
Methods: The levels of autoantibodies and 184 inflammatory and organ damage associated proteins in plasma were determined (by immunofluorescence and Olink panels, respectively) 1 year after an acute infection by SARS-CoV-2 in 51 patients with PS (DLCO < 80% ref), 31 patients with LC and 31 patients fully recovered (Rec). PS was defined by the presence of reduced carbon monoxide diffusing capacity (DLCO) lower than 80% ref. LC was defined by the presence of chronic symptoms in the absence of an alternative diagnosis.
Results: We found that patients with PS or LC both showed increased levels than Rec of anti-microbial, immune cell activation and recruitment related proteins. Patients with PS showed higher levels of anti-nuclear autoantibodies, whereas LC patients had increased levels of organ-damage associated proteins. In patients with PS most of the elevated proteins correlate with the impairment of lung function (DLCO). Finally, in PS we additionally performed the determinations at an earlier time point (6 months) and showed that the expression of CCL20 and IFN-ɣ was already higher at 6 months, while CCL3 and CCL19 increase from 6 to 12 months, suggesting a pathogenic role in PS persistence.
Conclusions: Patients with PS or LC have abnormal but different persistent circulatory immune and organ damage biomarkers, suggesting different underlying biology of both post-COVID conditions.

Keywords: 1 year of convalescence; Autoantibodies; Biomarkers; COVID-19; Long COVID; Organ-damage markers; Persistence of viral reservoirs; Pulmonary Sequelae.

 
Back
Top Bottom